Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anton Alvarez

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Medicinal Research Reviews|August 19, 2020
Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical useSvetlana I Gavrilova, Anton Alvarez
Medicinal Research Reviews|April 13, 2023
Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: Effects of CerebrolysinKonrad Rejdak, Halina Sienkiewicz-Jarosz, Przemyslaw Bienkowski, et al.
International Clinical Psychopharmacology|February 25, 2005
Effects of N-PEP-12 on memory among older adultsThomas H Crook, Steven H Ferris, X Anton Alvarez, et al.
Frontiers in Psychology|October 29, 2020
Neuromarketing Highlights in How Asperger Syndrome Youth Perceive AdvertisingPatricia Nuñez-Gomez, Anton Alvarez-Ruiz, Felix Ortega-Mohedano, et al.
Environmental Science & Technology|December 21, 2016
Development and Application of a Life Cycle-Based Model to Evaluate Greenhouse Gas Emissions of Oil Sands Upgrading TechnologiesDiana M Pacheco, Joule A Bergerson, Anton Alvarez-Majmutov, et al.
Journal of Alzheimer'S Disease : JAD|May 2, 2018
Severity-Related Increase and Cognitive Correlates of Serum VEGF Levels in Alzheimer's Disease ApoE4 CarriersX Anton Alvarez, Irene Alvarez, Manuel Aleixandre, et al.
The International Journal of Neuropsychopharmacology|June 18, 2009
Reduced TNF-α and increased IGF-I levels in the serum of Alzheimer's disease patients treated with the neurotrophic agent cerebrolysinX Anton Alvarez, Carolina Sampedro, Ramon Cacabelos, et al.
Journal of the Neurological Sciences|December 1, 2007
A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG accelerationDafin F Muresanu, X Anton Alvarez, Herbert Moessler, et al.
Journal of the Neurological Sciences|October 7, 2010
Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension studyDafin F Muresanu, X Anton Alvarez, Herbert Moessler, et al.
Journal of Neuroscience Research|July 28, 2011
Beneficial effects of a neurotrophic peptidergic mixture persist for a prolonged period following treatment interruption in a transgenic model of Alzheimer's diseaseEdward Rockenstein, Kiren Ubhi, Emiley Pham, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Medicinal Research Reviews|August 19, 2020
Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical useSvetlana I Gavrilova, Anton Alvarez
Medicinal Research Reviews|April 13, 2023
Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: Effects of CerebrolysinKonrad Rejdak, Halina Sienkiewicz-Jarosz, Przemyslaw Bienkowski, et al.
International Clinical Psychopharmacology|February 25, 2005
Effects of N-PEP-12 on memory among older adultsThomas H Crook, Steven H Ferris, X Anton Alvarez, et al.
Frontiers in Psychology|October 29, 2020
Neuromarketing Highlights in How Asperger Syndrome Youth Perceive AdvertisingPatricia Nuñez-Gomez, Anton Alvarez-Ruiz, Felix Ortega-Mohedano, et al.
Environmental Science & Technology|December 21, 2016
Development and Application of a Life Cycle-Based Model to Evaluate Greenhouse Gas Emissions of Oil Sands Upgrading TechnologiesDiana M Pacheco, Joule A Bergerson, Anton Alvarez-Majmutov, et al.
Journal of Alzheimer'S Disease : JAD|May 2, 2018
Severity-Related Increase and Cognitive Correlates of Serum VEGF Levels in Alzheimer's Disease ApoE4 CarriersX Anton Alvarez, Irene Alvarez, Manuel Aleixandre, et al.
The International Journal of Neuropsychopharmacology|June 18, 2009
Reduced TNF-α and increased IGF-I levels in the serum of Alzheimer's disease patients treated with the neurotrophic agent cerebrolysinX Anton Alvarez, Carolina Sampedro, Ramon Cacabelos, et al.
Journal of the Neurological Sciences|December 1, 2007
A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG accelerationDafin F Muresanu, X Anton Alvarez, Herbert Moessler, et al.
Journal of the Neurological Sciences|October 7, 2010
Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension studyDafin F Muresanu, X Anton Alvarez, Herbert Moessler, et al.
Journal of Neuroscience Research|July 28, 2011
Beneficial effects of a neurotrophic peptidergic mixture persist for a prolonged period following treatment interruption in a transgenic model of Alzheimer's diseaseEdward Rockenstein, Kiren Ubhi, Emiley Pham, et al.
Pageof 2